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shaped relationship to weight (BMI) indicating potential
cost offsets by effective weight-loss intervention.
CARDIOVASULAR DISEASES/DISORDERS—
Clinical Outcomes
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OBJECTIVES: Patients with Heart Failure (HF) are
known to have poor compliance even with medications
that can help reduce mortality and events such as 
readmissions. We wanted to examine whether compliance
with three such medications, primarily ACE-Inhibitors,
Digoxin and Spironolactone would have any impact on
the time to an event in HF patients. An event was deﬁned
as a readmission to hospital, an emergency room visit fol-
lowing a discharge from the index admission or death.
METHODS: Patients with HF who were admitted to the
London Health Sciences Centre were stratiﬁed then ran-
domized to receive either usual care education (U) or an
enhanced educational intervention (I) aimed at improving
compliance that was delivered in hospital, prior to dis-
charge. Compliance data was collected from pharmacy
reﬁll data from baseline over the period of follow-up that
was 12 months. A Cox Regression time-to-event analysis
was run for all patients adjusting for randomization ARM
and then adjusting for the covariates of interest, the
minimum and mean compliance. RESULTS: Seventy-ﬁve
out of 134 patients had an event. There was no difference
in time to event by ARM. The inclusion of the minimum
and mean compliance of each drug individually in the
regression did not result in any signiﬁcant changes in the
time-to-event; however, there was a trend p = 0.082 in
patients who were on spironolactone and had compliance
<0.80. CONCLUSIONS: We can hypothesize that there
may be a differential effect on the time to an event in this
population depending upon the medication. We should be
careful not to group all medication compliance into one
composite number as different medications in HF have
different effects on survival. This data warrants a more
careful assessment of compliance for each HF medication
and a determination of its effect on clinical outcomes of
interest.
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OBJECTIVES: Clinical trials have demonstrated
improved outcomes in patients receiving cholesterol low-
ering medications (CLM) following coronary revascu-
larization and clinical guidelines recommend aggressive
cholesterol lowering therapy for patients with established
coronary disease. However, in routine practice, the degree
to which these recommendations are followed and their
impact are unknown. METHODS: Using administrative
databases, we examined the use of CLM in a consecutive
cohort of 11,985 elderly (average age 71.4) patients
undergoing coronary revascularization from 1995 until
1997 in Quebec, Canada. RESULTS: Before revascular-
ization, 30.9% were receiving CLM. After a 3-year
follow-up, 62.8% of cohort survivors had received at
least 1 prescription for CLM. CABG patients had a
decreased probability of receiving CLM compared to PCI
patients (OR .75 95% CI .72–.79). High-risk patients
especially the very elderly (>75) had a signiﬁcantly
decreased probability of receiving CLM (OR .61 95% CI
.57–.66). The most potent predictor of a post-operative
prescription use was pre-operative utilization (OR 7.1
95% CI 6.8–7.5). An adjusted time-dependent analysis
showed that patients receiving CLM had a lower risk of
death (RR 0.61 95% CI 0.52–0.79) or myocardial infarc-
tion (RR 0.78 95% CI 0.64–0.93) than those not exposed
to these drugs. There was no difference in the need for a
repeat revascularization between the groups (RR 1.05
95% CI 0.91–1.20). CONCLUSIONS: CLM were under-
used in this post revascularization population and this
underuse was associated with an increase in adverse 
outcomes.
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MANAGEMENT OF PULMONARY 
ARTERIAL HYPERTENSION
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Pulmonary arterial hypertension (PAH) is a rare, incur-
able and often fatal disorder of the lung in which pul-
monary artery pressure rises to abnormal levels. It may
either be idiopathic in nature (primary pulmonary hyper-
tension) or a manifestation of many different disorders
(secondary pulmonary hypertension). Current manage-
ment includes prostacyclin vasodilator therapy, and con-
ventional therapy consisting of calcium channel blockers,
anticoagulation, oxygen therapy and diueresis; and newer
agents such as bosentan, an endothelin antagonist. To
date, no systematic review has assessed these interven-
tions. OBJECTIVES: To perform a systematic review of
the medical interventions used in the management of
PAH. METHODS: A literature search of EMBASE and
MEDLINE was performed, and studies matching the pre-
deﬁned inclusion criteria extracted to HTA-standardised
grids and graded using the Jadad score. Data for three
outcome measures survival, exercise capacity and right
